Karol Sikora – författare

This 2006 book examines the interaction of economics and the delivery of cancer care in the global context. It analyses the causes of tension between those paying for care, those providing the care and those marketing drugs and devices. The concept and requirement for rationing is examined in different economic environments. As cancer increases in incidence and prevalence, the economics of providing care becomes a more important subject than ever before. Written by a leading health economist and oncologist, this was the first comprehensive book on the economics of cancer care continues to be of interest to health professionals and policy makers alike.

One third of human cancers have a hormonal basis. Breast cancer, the most common cancer of women, is increasing in incidence in many countries, as, in epidemic proportions, is prostate cancer, the second most common cancer of men. Concurrently, the development of molecular biology has led to a refinement of the definition of hormones to include the complex interaction between tumour cells and both locally and distantly secreted factors. This 1996 volume from the series Cancer: Clinical Science in Practice considers the many aspects of hormonally dependent cancer, including the molecular basis for the autocrine and paracrine regulation of cancer, molecular strategies for cancer detection, preventive strategies in limiting the epidemic of hormonally related cancers, and treatment approaches. The concise volumes in this series are intended for a wide audience of clinicians and researchers with an interest in the application of biomedical science to the understanding and management of cancer.

This 2006 book examines the interaction of economics and the delivery of cancer care in the global context. It analyses the causes of tension between those paying for care, those providing the care and those marketing drugs and devices. The concept and requirement for rationing is examined in different economic environments. As cancer increases in incidence and prevalence, the economics of providing care becomes a more important subject than ever before. Written by a leading health economist and oncologist, this was the first comprehensive book on the economics of cancer care continues to be of interest to health professionals and policy makers alike.

This successful text is a comprehensive guide to modern cancer treatments that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.

Interferon was first discovered in 1957. Over the last five years it has become almost a household word. Many believe it to be a drug with already proven efficacy against cancer and viral infection. The media has distorted any cool scientific view of the data available. We have learned much about the complexity of the interferon system. We know some of the switches involved in interferon gene expression and its secretion by virally and immune stimulated cells. We also know that it binds to a cell surface receptor, mediating its complex effects on target cells by a series of second messengers. The advent of the new techniques of modern molecular biology, such as monoclonal antibodies and gene cloning, has had tremendous impact on the rate of acquisition of knowledge. Such techniques have provided us with almost unlimited quantities of highly purified interferon for clinical trial in patients with a spectrum of infectious and malignant diseases. The information we have gathered raises many more questions. Why should there be several families of interferon genes? What is their true physiolo­ gical role? How are they interrelated functionally? Interferon is clearly a cellular hormone providing a means of communication between cells. ~fhether it has clinical value in the management of patients with diseased cells remains to be seen. This book sum­ marises our current knowledge of interferons as possible an- cancer agents. It is clear interferon is no penicillin for cancer.

Interferon was first discovered in 1957. Over the last five years it has become almost a household word. Many believe it to be a drug with already proven efficacy against cancer and viral infection. The media has distorted any cool scientific view of the data available. We have learned much about the complexity of the interferon system. We know some of the switches involved in interferon gene expression and its secretion by virally and immune stimulated cells. We also know that it binds to a cell surface receptor, mediating its complex effects on target cells by a series of second messengers. The advent of the new techniques of modern molecular biology, such as monoclonal antibodies and gene cloning, has had tremendous impact on the rate of acquisition of knowledge. Such techniques have provided us with almost unlimited quantities of highly purified interferon for clinical trial in patients with a spectrum of infectious and malignant diseases. The information we have gathered raises many more questions. Why should there be several families of interferon genes? What is their true physiolo­ gical role? How are they interrelated functionally? Interferon is clearly a cellular hormone providing a means of communication between cells. ~fhether it has clinical value in the management of patients with diseased cells remains to be seen. This book sum­ marises our current knowledge of interferons as possible an- cancer agents. It is clear interferon is no penicillin for cancer.

Endocrine Problems in Cancer: Molecular Basis and Clinical Management reviews endocrine and metabolic problems that can be attributed to the production of hormones by neoplastic cells, or by the interference of normal physiological systems by malignant cells. The book emphasizes the clinical aspects of the diagnosis and management of the endocrine problems in cancer. The text starts by studying the biological basis of cancer, its secreted products, and its relationship to the genetics of the cell and the individual. Cell metabolism and the individual clinical endocrine syndromes that occur are then discussed in the chapters that follow. Several chapters describe the physiological basis and the diagnostic approach to cancer. Finally, the clinical management of cancer is outlined in detail. Oncologists, endocrinologists, physicians, researchers, and medical students will find this text useful.